Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer.
Identifieur interne : 001041 ( Main/Exploration ); précédent : 001040; suivant : 001042Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer.
Auteurs : Hannah A. Blair [Nouvelle-Zélande]Source :
- Targeted oncology [ 1776-260X ] ; 2018.
Descripteurs français
- KwdFr :
- Analyse de survie (MeSH), Anticorps monoclonaux (pharmacologie), Anticorps monoclonaux (usage thérapeutique), Anticorps monoclonaux humanisés (MeSH), Carcinome pulmonaire non à petites cellules (anatomopathologie), Carcinome pulmonaire non à petites cellules (mortalité), Carcinome pulmonaire non à petites cellules (traitement médicamenteux), Humains (MeSH), Tumeurs du poumon (anatomopathologie), Tumeurs du poumon (mortalité), Tumeurs du poumon (traitement médicamenteux).
- MESH :
- anatomopathologie : Carcinome pulmonaire non à petites cellules, Tumeurs du poumon.
- mortalité : Carcinome pulmonaire non à petites cellules, Tumeurs du poumon.
- pharmacologie : Anticorps monoclonaux.
- traitement médicamenteux : Carcinome pulmonaire non à petites cellules, Tumeurs du poumon.
- usage thérapeutique : Anticorps monoclonaux.
- Analyse de survie, Anticorps monoclonaux humanisés, Humains.
English descriptors
- KwdEn :
- Antibodies, Monoclonal (pharmacology), Antibodies, Monoclonal (therapeutic use), Antibodies, Monoclonal, Humanized (MeSH), Carcinoma, Non-Small-Cell Lung (drug therapy), Carcinoma, Non-Small-Cell Lung (mortality), Carcinoma, Non-Small-Cell Lung (pathology), Humans (MeSH), Lung Neoplasms (drug therapy), Lung Neoplasms (mortality), Lung Neoplasms (pathology), Survival Analysis (MeSH).
- MESH :
- chemical , pharmacology : Antibodies, Monoclonal.
- chemical , therapeutic use : Antibodies, Monoclonal.
- chemical : Antibodies, Monoclonal, Humanized.
- drug therapy : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- mortality : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- pathology : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- Humans, Survival Analysis.
Abstract
Atezolizumab (TECENTRIQ™), an immune checkpoint inhibitor, is an immunoglobulin G1 monoclonal antibody that binds to programmed death ligand 1 (PD-L1) and blocks its interactions with programmed death 1 and B7.1 receptors. Atezolizumab is approved as monotherapy in several countries worldwide for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who have previously received chemotherapy. Approval was based on its clinical benefit in this setting in the phase II POPLAR and phase III OAK trials. In these studies, atezolizumab significantly prolonged overall survival (OS) relative to docetaxel, regardless of PD-L1 status. Increasing PD-L1 expression was associated with OS improvements. Atezolizumab also demonstrated efficacy in the phase II FIR and BIRCH trials, as assessed by objective response rates (ORRs) in patients with tumours expressing PD-L1. Higher ORRs were seen in patients with high PD-L1 expression. Atezolizumab had an acceptable, manageable tolerability profile, with a low incidence of immune-related adverse events. Therefore, atezolizumab is a valuable treatment option for patients with advanced NSCLC that has progressed during or after chemotherapy.
DOI: 10.1007/s11523-018-0570-5
PubMed: 29785577
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer.</title><author><name sortKey="Blair, Hannah A" sort="Blair, Hannah A" uniqKey="Blair H" first="Hannah A" last="Blair">Hannah A. Blair</name><affiliation wicri:level="1"><nlm:affiliation>Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.</nlm:affiliation><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754</wicri:regionArea><wicri:noRegion>0754</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29785577</idno><idno type="pmid">29785577</idno><idno type="doi">10.1007/s11523-018-0570-5</idno><idno type="wicri:Area/Main/Corpus">000E23</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000E23</idno><idno type="wicri:Area/Main/Curation">000E23</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000E23</idno><idno type="wicri:Area/Main/Exploration">000E23</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer.</title><author><name sortKey="Blair, Hannah A" sort="Blair, Hannah A" uniqKey="Blair H" first="Hannah A" last="Blair">Hannah A. Blair</name><affiliation wicri:level="1"><nlm:affiliation>Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.</nlm:affiliation><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754</wicri:regionArea><wicri:noRegion>0754</wicri:noRegion></affiliation></author></analytic><series><title level="j">Targeted oncology</title><idno type="eISSN">1776-260X</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal (pharmacology)</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (MeSH)</term><term>Carcinoma, Non-Small-Cell Lung (drug therapy)</term><term>Carcinoma, Non-Small-Cell Lung (mortality)</term><term>Carcinoma, Non-Small-Cell Lung (pathology)</term><term>Humans (MeSH)</term><term>Lung Neoplasms (drug therapy)</term><term>Lung Neoplasms (mortality)</term><term>Lung Neoplasms (pathology)</term><term>Survival Analysis (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Analyse de survie (MeSH)</term><term>Anticorps monoclonaux (pharmacologie)</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Anticorps monoclonaux humanisés (MeSH)</term><term>Carcinome pulmonaire non à petites cellules (anatomopathologie)</term><term>Carcinome pulmonaire non à petites cellules (mortalité)</term><term>Carcinome pulmonaire non à petites cellules (traitement médicamenteux)</term><term>Humains (MeSH)</term><term>Tumeurs du poumon (anatomopathologie)</term><term>Tumeurs du poumon (mortalité)</term><term>Tumeurs du poumon (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Anticorps monoclonaux</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Survival Analysis</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse de survie</term><term>Anticorps monoclonaux humanisés</term><term>Humains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Atezolizumab (TECENTRIQ™), an immune checkpoint inhibitor, is an immunoglobulin G1 monoclonal antibody that binds to programmed death ligand 1 (PD-L1) and blocks its interactions with programmed death 1 and B7.1 receptors. Atezolizumab is approved as monotherapy in several countries worldwide for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who have previously received chemotherapy. Approval was based on its clinical benefit in this setting in the phase II POPLAR and phase III OAK trials. In these studies, atezolizumab significantly prolonged overall survival (OS) relative to docetaxel, regardless of PD-L1 status. Increasing PD-L1 expression was associated with OS improvements. Atezolizumab also demonstrated efficacy in the phase II FIR and BIRCH trials, as assessed by objective response rates (ORRs) in patients with tumours expressing PD-L1. Higher ORRs were seen in patients with high PD-L1 expression. Atezolizumab had an acceptable, manageable tolerability profile, with a low incidence of immune-related adverse events. Therefore, atezolizumab is a valuable treatment option for patients with advanced NSCLC that has progressed during or after chemotherapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29785577</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1776-260X</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>06</Month></PubDate></JournalIssue><Title>Targeted oncology</Title><ISOAbbreviation>Target Oncol</ISOAbbreviation></Journal><ArticleTitle>Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer.</ArticleTitle><Pagination><MedlinePgn>399-407</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11523-018-0570-5</ELocationID><Abstract><AbstractText>Atezolizumab (TECENTRIQ™), an immune checkpoint inhibitor, is an immunoglobulin G1 monoclonal antibody that binds to programmed death ligand 1 (PD-L1) and blocks its interactions with programmed death 1 and B7.1 receptors. Atezolizumab is approved as monotherapy in several countries worldwide for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who have previously received chemotherapy. Approval was based on its clinical benefit in this setting in the phase II POPLAR and phase III OAK trials. In these studies, atezolizumab significantly prolonged overall survival (OS) relative to docetaxel, regardless of PD-L1 status. Increasing PD-L1 expression was associated with OS improvements. Atezolizumab also demonstrated efficacy in the phase II FIR and BIRCH trials, as assessed by objective response rates (ORRs) in patients with tumours expressing PD-L1. Higher ORRs were seen in patients with high PD-L1 expression. Atezolizumab had an acceptable, manageable tolerability profile, with a low incidence of immune-related adverse events. Therefore, atezolizumab is a valuable treatment option for patients with advanced NSCLC that has progressed during or after chemotherapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Blair</LastName><ForeName>Hannah A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Target Oncol</MedlineTA><NlmUniqueID>101270595</NlmUniqueID><ISSNLinking>1776-2596</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>52CMI0WC3Y</RegistryNumber><NameOfSubstance UI="C000594389">atezolizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29785577</ArticleId><ArticleId IdType="doi">10.1007/s11523-018-0570-5</ArticleId><ArticleId IdType="pii">10.1007/s11523-018-0570-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Invest New Drugs. 2016 Oct;34(5):596-603</Citation><ArticleIdList><ArticleId IdType="pubmed">27363843</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2018 Mar 20;36(9):850-858</Citation><ArticleIdList><ArticleId IdType="pubmed">29341833</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Clin Pharmacol. 2017 Sep;10(9):935-945</Citation><ArticleIdList><ArticleId IdType="pubmed">28714780</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2017 Aug 20;35(24):2781-2789</Citation><ArticleIdList><ArticleId IdType="pubmed">28609226</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2017 Jan 21;389(10066):255-265</Citation><ArticleIdList><ArticleId IdType="pubmed">27979383</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2014 Nov 27;515(7528):563-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25428504</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Pharmacol. 2017 Aug 23;8:561</Citation><ArticleIdList><ArticleId IdType="pubmed">28878676</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Lung Cancer. 2018 Jul;19(4):e405-e415</Citation><ArticleIdList><ArticleId IdType="pubmed">29525239</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2016 Apr 30;387(10030):1837-46</Citation><ArticleIdList><ArticleId IdType="pubmed">26970723</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 2018 Mar 15;142(6):1277-1284</Citation><ArticleIdList><ArticleId IdType="pubmed">29080213</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med. 2017 Oct 30;15(1):193</Citation><ArticleIdList><ArticleId IdType="pubmed">29082855</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Cancer Res. 2012 Dec 15;18(24):6580-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23087408</ArticleId></ArticleIdList></Reference><Reference><Citation>Open Biol. 2017 Sep;7(9):</Citation><ArticleIdList><ArticleId IdType="pubmed">28878044</ArticleId></ArticleIdList></Reference><Reference><Citation>Lung Cancer. 2018 Jan;115:84-88</Citation><ArticleIdList><ArticleId IdType="pubmed">29290267</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142</Citation><ArticleIdList><ArticleId IdType="pubmed">28881921</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Lung Cancer Res. 2016 Jun;5(3):288-300</Citation><ArticleIdList><ArticleId IdType="pubmed">27413711</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Nouvelle-Zélande</li></country></list><tree><country name="Nouvelle-Zélande"><noRegion><name sortKey="Blair, Hannah A" sort="Blair, Hannah A" uniqKey="Blair H" first="Hannah A" last="Blair">Hannah A. Blair</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001041 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001041 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PoplarV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:29785577
|texte= Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:29785577" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PoplarV1
| This area was generated with Dilib version V0.6.37. |  |